Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by November 18, 2025 [1][3]. Company Overview - Jasper Therapeutics, Inc. is facing scrutiny for allegedly lacking necessary controls and procedures for third-party manufacturers, which may have impacted the integrity of clinical trials and the prospects of its products, particularly briquilimab [3]. Legal Allegations - The complaint against Jasper claims that the company made false or misleading statements regarding its manufacturing processes and the viability of its clinical trials, which could lead to overstated business and financial prospects [3]. - Specific allegations include the failure to ensure compliance with current Good Manufacturing Practices (cGMP), which increased the risk of confounded study results and potential cost-reduction measures [3]. Recent Developments - On July 7, 2025, Jasper reported issues with a drug product lot used in clinical trials, leading to a significant drop in stock price by $3.73 per share, or 55.1%, closing at $3.04 per share [4]. - The company announced a halt in the ETESIAN Study and paused development in asthma and SCID, contradicting previous statements about its financial stability and cash runway [4]. Investor Actions - Investors who suffered losses between November 30, 2023, and July 3, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][6]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Jasper's conduct [6].